BRPI0817681A2 - Compostos de tienopirimidina e pirazolopirimidina e seu uso como inibidores de mtor quinase e pi3 quinase - Google Patents

Compostos de tienopirimidina e pirazolopirimidina e seu uso como inibidores de mtor quinase e pi3 quinase

Info

Publication number: BRPI0817681A2
Authority: BR; Brazil
Prior art keywords: kinase; tienopyrimidine; pirazolopyrimidine; compounds; mtor
Prior art date: 2007-10-16

Application number

Other languages

English (en)

Inventor

Arie Zask

Joshua Aaron Kaplan

Jeroen Cunera Verheijen

Kevin Joseph Curran

David James Richard

Semiramis Ayral-Kaloustian

Original Assignee

Wyeth Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-16

Filing date

2008-10-15

Publication date

2015-04-14

2008-10-15 Application filed by Wyeth Llc filed Critical Wyeth Llc

2015-04-14 Publication of BRPI0817681A2 publication Critical patent/BRPI0817681A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Transplantation (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0817681 2007-10-16 2008-10-15 Compostos de tienopirimidina e pirazolopirimidina e seu uso como inibidores de mtor quinase e pi3 quinase BRPI0817681A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US98033207P	2007-10-16	2007-10-16
US2759508P	2008-02-11	2008-02-11
PCT/US2008/079940 WO2009052145A1 (en)	2007-10-16	2008-10-15	Thienopyrimidine and pyrazolopyrimidine compounds and their use as mtor kinase and pi3 kinase inhibitors

Publications (1)

Publication Number	Publication Date
BRPI0817681A2 true BRPI0817681A2 (pt)	2015-04-14

Family

ID=40345078

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0817681 BRPI0817681A2 (pt)	2007-10-16	2008-10-15	Compostos de tienopirimidina e pirazolopirimidina e seu uso como inibidores de mtor quinase e pi3 quinase

Country Status (26)

Country	Link
US (1)	US8129371B2 (pt)
EP (1)	EP2212333A1 (pt)
JP (1)	JP2011500702A (pt)
KR (1)	KR20100083170A (pt)
CN (1)	CN101883774A (pt)
AP (1)	AP2010005234A0 (pt)
AR (1)	AR068898A1 (pt)
AU (1)	AU2008312631A1 (pt)
BR (1)	BRPI0817681A2 (pt)
CA (1)	CA2702838A1 (pt)
CL (1)	CL2008003061A1 (pt)
CO (1)	CO6321257A2 (pt)
CR (1)	CR11373A (pt)
DO (1)	DOP2010000118A (pt)
EA (1)	EA201000484A1 (pt)
EC (1)	ECSP10010112A (pt)
IL (1)	IL205109A0 (pt)
MA (1)	MA31884B1 (pt)
MX (1)	MX2010004260A (pt)
NI (1)	NI201000060A (pt)
PA (1)	PA8799101A1 (pt)
PE (1)	PE20091384A1 (pt)
TN (1)	TN2010000171A1 (pt)
TW (1)	TW200922593A (pt)
WO (1)	WO2009052145A1 (pt)
ZA (1)	ZA201003430B (pt)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69636466T2 (de) *	1996-09-04	2007-08-09	Intertrust Technologies Corp., Sunnyvale	Treuhand infrastruktur unterstützungssysteme, verfahren und techniken zum sicheren elektronischen handel, elektronische transaktionen, steuerung und automatisierung von handelsverfahren, verteilte datenverarbeitung und verwalten von rechten
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
EP2295080A3 (en)	2005-07-25	2011-06-22	Emergent Product Development Seattle, LLC	B-cell reduction using CD37-specific and CD20-specific binding molecules
CN105837690A (zh)	2006-06-12	2016-08-10	新兴产品开发西雅图有限公司	具有效应功能的单链多价结合蛋白
PE20091268A1 (es)	2007-12-19	2009-09-19	Amgen Inc	Derivados heterociclicos como inhibidores de pi3 quinasa
PT2132228E (pt)	2008-04-11	2011-10-11	Emergent Product Dev Seattle	Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
TW201004963A (en) *	2008-07-03	2010-02-01	Targacept Inc	Derivatives of oxabispidine as neuronal nicotinic acetylcholine receptor ligands
EP2318377B1 (en) *	2008-07-31	2013-08-21	Genentech, Inc.	Pyrimidine compounds, compositions and methods of use
RS53350B (sr)	2008-09-22	2014-10-31	Array Biopharma, Inc.	Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze
TWI378933B (en)	2008-10-14	2012-12-11	Daiichi Sankyo Co Ltd	Morpholinopurine derivatives
HRP20140309T1 (hr)	2008-10-22	2014-05-09	Array Biopharma, Inc.	SUPSTITUIRANI SPOJEVI PIRAZOLO[1,5-a]PIRIMIDINA KAO INHIBITORI TRK KINAZE
EP2385832B1 (en)	2009-01-08	2015-07-15	Curis, Inc.	Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
ES2439793T3 (es) *	2009-04-17	2014-01-24	Wyeth Llc	Compuestos de pirimidina, su uso como inhibidores de la mTOR quinasa y de la PI3 quinasa, y su síntesis
SG175708A1 (en) *	2009-05-27	2011-12-29	Genentech Inc	Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
US20100331305A1 (en) *	2009-06-24	2010-12-30	Genentech, Inc.	Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
AR077468A1 (es)	2009-07-09	2011-08-31	Array Biopharma Inc	Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US20110021515A1 (en) *	2009-07-24	2011-01-27	Takeda Pharmaceutical Company Limited	Dihyrofuropyrmindine compounds
KR101147550B1 (ko) *	2009-10-22	2012-05-17	한국과학기술연구원	단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노［3,2-ｄ］피리미딘 화합물
CN102711766B (zh) *	2009-11-12	2014-06-04	霍夫曼-拉罗奇有限公司	N-9-取代的嘌呤化合物、组合物和使用方法
CN102712642B (zh) *	2009-11-12	2015-08-12	霍夫曼-拉罗奇有限公司	N-7取代的嘌呤和吡唑并嘧啶化合物、组合物和使用方法
WO2011078795A1 (en) *	2009-12-21	2011-06-30	S*Bio Pte Ltd	Bridged morpholino substituted purines
EP2525659B1 (en) *	2010-01-19	2019-02-27	Merck Sharp & Dohme Corp.	PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
SG183155A1 (en)	2010-02-03	2012-09-27	Signal Pharm Llc	Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
WO2011125012A1 (en)	2010-04-05	2011-10-13	Wyeth Llc	Biomarkers for p13k-driven cancer
KR102015402B1 (ko)	2010-05-20	2019-08-28	어레이 바이오파마 인크.	Trk 키나제 저해제로서의 매크로시클릭 화합물
EP3399026B1 (en)	2010-06-14	2024-06-26	The Scripps Research Institute	Reprogramming of cells to a new fate
AU2011332867A1 (en) *	2010-11-24	2013-06-20	Exelixis, Inc.	BENZOXAZEPINES AS INHIBITORS OF PI3K/mTOR AND METHODS OF THEIR USE AND MANUFACTURE
WO2012088266A2 (en)	2010-12-22	2012-06-28	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2012099581A1 (en)	2011-01-19	2012-07-26	Takeda Pharmaceutical Company Limited	Dihydrofuropyrimidine compounds
US20130158023A1 (en)	2011-08-03	2013-06-20	Signal Pharmaceuticals, Llc	Identification of gene expression as a predictive biomarker for lkb1 status
FR2985257B1 (fr) *	2011-12-28	2014-02-14	Sanofi Sa	Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
CN104080789B (zh) *	2012-01-31	2016-05-11	南京奥昭生物科技有限公司	作为布鲁顿酪氨酸激酶抑制剂的环状分子
WO2013152717A1 (zh) *	2012-04-10	2013-10-17	上海昀怡健康管理咨询有限公司	稠合嘧啶类化合物，其制备方法，中间体，组合物和应用
CN103374021B (zh) *	2012-04-21	2015-10-28	通化济达医药有限公司	含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂
EP2852661A1 (en)	2012-05-23	2015-04-01	F. Hoffmann-La Roche AG	Compositions and methods of obtaining and using endoderm and hepatocyte cells
CN103450204B (zh) *	2012-05-31	2016-08-17	中国科学院上海药物研究所	吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
LT3495367T (lt)	2012-06-13	2021-02-25	Incyte Holdings Corporation	Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
WO2014026125A1 (en)	2012-08-10	2014-02-13	Incyte Corporation	Pyrazine derivatives as fgfr inhibitors
AU2013203714B2 (en)	2012-10-18	2015-12-03	Signal Pharmaceuticals, Llc	Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
US9505764B2 (en)	2013-04-17	2016-11-29	Signal Pharmaceuticals, Llc	Treatment of cancer with dihydropyrazino-pyrazines
HK1221168A1 (zh)	2013-04-17	2017-05-26	西格诺药品有限公司	用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法
MX368286B (es)	2013-04-17	2019-09-27	Signal Pharm Llc	Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
EA030726B1 (ru)	2013-04-17	2018-09-28	СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи	ФАРМАЦЕВТИЧЕСКИЕ СОСТАВЫ, СПОСОБЫ, ТВЕРДЫЕ ФОРМЫ И СПОСОБЫ ПРИМЕНЕНИЯ, ОТНОСЯЩИЕСЯ К 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1H)-ОНУ
CA2908957C (en)	2013-04-17	2021-05-18	Signal Pharmaceuticals, Llc	Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
AU2014254059B2 (en)	2013-04-17	2019-06-06	Signal Pharmaceuticals, Llc	Combination therapy comprising a TOR kinase inhibitor and a cytidine analog for treating cancer
CA2908353C (en)	2013-04-17	2021-11-02	Signal Pharmaceuticals, Llc	Treatment of cancer with dihydropyrazino-pyrazines
LT2986610T (lt)	2013-04-19	2018-04-10	Incyte Holdings Corporation	Bicikliniai heterociklai, kaip fgfr inhibitoriai
HK1223286A1 (zh)	2013-05-29	2017-07-28	西格诺药品有限公司	7-(6-(2-羟基丙-2-基)吡啶-3-基)-1-((反式)-4-甲氧基环己基)-3，4-二氢吡嗪并[2，3-b]吡嗪-2(1h)-酮的药物组合物、其固体形式及它们的使用方法
CA2928568A1 (en)	2013-07-26	2015-01-29	Update Pharma Inc.	Combinatorial methods to improve the therapeutic benefit of bisantrene
JP6441910B2 (ja) *	2013-09-30	2018-12-19	シャンハイインリファーマシューティカルカンパニーリミティド	縮合ピリミジン化合物、中間体、その調製方法、組成物及び使用
FR3015483B1 (fr) *	2013-12-23	2016-01-01	Servier Lab	Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US9763992B2 (en)	2014-02-13	2017-09-19	Father Flanagan's Boys' Home	Treatment of noise induced hearing loss
NZ714742A (en)	2014-04-16	2017-04-28	Signal Pharm Llc	Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
JP2017511367A (ja)	2014-04-16	2017-04-20	シグナルファーマシューティカルズ，エルエルシー	１−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン及び共形成物を含む固体形態、その組成物及び使用方法
CN106459048A (zh)	2014-05-14	2017-02-22	辉瑞公司	吡唑并吡啶类和吡唑并嘧啶类
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
JP6914834B2 (ja)	2014-11-16	2021-08-04	アレイバイオファーマインコーポレイテッド	（Ｓ）−Ｎ−（５−（（Ｒ）−２−（２，５−ジフルオロフェニル）−ピロリジン−１−イル）−ピラゾロ［１，５−ａ］ピリミジン−３−イル）−３−ヒドロキシピロリジン−１−カルボキサミド硫酸水素塩の結晶形
WO2016134294A1 (en)	2015-02-20	2016-08-25	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
SG11201706287PA (en)	2015-02-20	2017-09-28	Incyte Corp	Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
KR102784293B1 (ko)	2015-09-21	2025-03-20	압테보 리서치 앤드 디벨롭먼트 엘엘씨	Cd3 결합 폴리펩타이드
TN2018000138A1 (en)	2015-10-26	2019-10-04	Array Biopharma Inc	Point mutations in trk inhibitor-resistant cancer and methods relating to the same
FR3046792B1 (fr) *	2016-01-19	2018-02-02	Les Laboratoires Servier	Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US10045991B2 (en)	2016-04-04	2018-08-14	Loxo Oncology, Inc.	Methods of treating pediatric cancers
AU2017246554B2 (en)	2016-04-04	2022-08-18	Loxo Oncology, Inc.	Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
KR102566858B1 (ko)	2016-05-18	2023-08-11	어레이 바이오파마 인크.	(s)-n-(5-((r)-2-(2,5-디플루오로페닐)피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-히드록시피롤리딘-1-카르복사미드의 제조 방법
JOP20190092A1 (ar)	2016-10-26	2019-04-25	Array Biopharma Inc	عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar)	2017-03-16	2019-09-16	Array Biopharma Inc	مركبات حلقية ضخمة كمثبطات لكيناز ros1
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
ES2959860T3 (es)	2017-06-22	2024-02-28	Celgene Corp	Tratamiento del carcinoma hepatocelular caracterizado por la infección por el virus de la hepatitis B
EP3749697A4 (en)	2018-02-05	2021-11-03	Bio-Rad Laboratories, Inc.	CHROMATOGRAPHY RESIN WITH LIGAND MIXED MODE ANIONIC / HYDROPHOBIC EXCHANGE
CN108358949A (zh) *	2018-03-01	2018-08-03	南京法恩化学有限公司	一种2，4-二氯噻吩并[3，2-d]嘧啶的制备方法
MX2020011718A (es)	2018-05-04	2021-02-15	Incyte Corp	Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
ES3061844T3 (en)	2018-05-04	2026-04-07	Incyte Corp	Salts of an fgfr inhibitor
CN110850012B (zh) *	2018-08-21	2022-07-08	四川弘远药业有限公司	一种1-(2,3-二氯苯基)哌嗪盐酸盐及其有关物质的检测方法
IL285020B2 (en)	2019-02-06	2025-11-01	Venthera Inc	Topical phosphoinositide 3-kinase inhibitors
CN111646995B (zh) *	2019-03-04	2023-03-21	四川大学	4-氨基-嘧啶并氮杂环-苯基脲类衍生物及其制备方法和用途
US11628162B2 (en)	2019-03-08	2023-04-18	Incyte Corporation	Methods of treating cancer with an FGFR inhibitor
CN109824701B (zh) *	2019-03-26	2021-08-13	武汉工程大学	一种吡啶并噻唑类化合物及其制备方法和应用
US11591329B2 (en)	2019-07-09	2023-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en)	2019-10-01	2024-10-22	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
EP3800188A1 (en)	2019-10-02	2021-04-07	Bayer AG	Substituted pyrazolopyrimidines as irak4 inhibitors
TWI891666B (zh)	2019-10-14	2025-08-01	美商英塞特公司	作為ｆｇｆｒ抑制劑之雙環雜環
US11566028B2 (en)	2019-10-16	2023-01-31	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
WO2021113462A1 (en)	2019-12-04	2021-06-10	Incyte Corporation	Derivatives of an fgfr inhibitor
CA3163875A1 (en)	2019-12-04	2021-06-10	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en)	2020-01-15	2024-06-18	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
TW202304459A (zh)	2021-04-12	2023-02-01	美商英塞特公司	包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
CN113278015B (zh) *	2021-05-31	2022-05-13	云南大学	一种荧光探针及其制备方法和应用
EP4352060A1 (en)	2021-06-09	2024-04-17	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
JP2024522189A (ja)	2021-06-09	2024-06-11	インサイト・コーポレイション	Ｆｇｆｒ阻害剤としての三環式ヘテロ環
TW202602891A (zh) *	2024-03-28	2026-01-16	大陸商勵締（杭州）醫藥科技有限公司	具有mTOR抑制活性的有機化合物及其用途
GB202415232D0 (en)	2024-10-16	2024-11-27	Nacamed As	Composition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU5261001A (en)	2000-04-27	2001-11-12	Imperial Cancer Research Technology Ltd	Condensed heteroaryl derivatives

2008
- 2008-10-15 CA CA2702838A patent/CA2702838A1/en not_active Abandoned
- 2008-10-15 BR BRPI0817681 patent/BRPI0817681A2/pt not_active Application Discontinuation
- 2008-10-15 AP AP2010005234A patent/AP2010005234A0/xx unknown
- 2008-10-15 KR KR1020107010683A patent/KR20100083170A/ko not_active Ceased
- 2008-10-15 US US12/251,712 patent/US8129371B2/en not_active Expired - Fee Related
- 2008-10-15 AU AU2008312631A patent/AU2008312631A1/en not_active Abandoned
- 2008-10-15 EP EP08839537A patent/EP2212333A1/en not_active Withdrawn
- 2008-10-15 JP JP2010530074A patent/JP2011500702A/ja not_active Withdrawn
- 2008-10-15 MX MX2010004260A patent/MX2010004260A/es not_active Application Discontinuation
- 2008-10-15 WO PCT/US2008/079940 patent/WO2009052145A1/en not_active Ceased
- 2008-10-15 CN CN2008801190434A patent/CN101883774A/zh active Pending
- 2008-10-15 EA EA201000484A patent/EA201000484A1/ru unknown
- 2008-10-16 AR ARP080104520A patent/AR068898A1/es unknown
- 2008-10-16 PE PE2008001780A patent/PE20091384A1/es not_active Application Discontinuation
- 2008-10-16 CL CL2008003061A patent/CL2008003061A1/es unknown
- 2008-10-16 TW TW097139718A patent/TW200922593A/zh unknown
- 2008-10-16 PA PA20088799101A patent/PA8799101A1/es unknown
2010
- 2010-04-15 IL IL205109A patent/IL205109A0/en unknown
- 2010-04-15 NI NI201000060A patent/NI201000060A/es unknown
- 2010-04-15 CR CR11373A patent/CR11373A/es not_active Application Discontinuation
- 2010-04-16 EC EC2010010112A patent/ECSP10010112A/es unknown
- 2010-04-16 MA MA32778A patent/MA31884B1/fr unknown
- 2010-04-16 DO DO2010000118A patent/DOP2010000118A/es unknown
- 2010-04-16 TN TN2010000171A patent/TN2010000171A1/fr unknown
- 2010-04-20 CO CO10046199A patent/CO6321257A2/es not_active Application Discontinuation
- 2010-05-14 ZA ZA2010/03430A patent/ZA201003430B/en unknown

Also Published As

Publication number	Publication date
MX2010004260A (es)	2010-04-30
IL205109A0 (en)	2010-11-30
ECSP10010112A (es)	2010-08-31
CR11373A (es)	2010-05-03
WO2009052145A1 (en)	2009-04-23
NI201000060A (es)	2010-10-04
EP2212333A1 (en)	2010-08-04
PA8799101A1 (es)	2009-05-15
US20090098086A1 (en)	2009-04-16
CO6321257A2 (es)	2011-09-20
TN2010000171A1 (fr)	2011-11-11
AR068898A1 (es)	2009-12-16
PE20091384A1 (es)	2009-09-09
US8129371B2 (en)	2012-03-06
AP2010005234A0 (en)	2010-04-30
CL2008003061A1 (es)	2009-01-09
CN101883774A (zh)	2010-11-10
MA31884B1 (fr)	2010-12-01
TW200922593A (en)	2009-06-01
AU2008312631A1 (en)	2009-04-23
EA201000484A1 (ru)	2010-12-30
JP2011500702A (ja)	2011-01-06
CA2702838A1 (en)	2009-04-23
DOP2010000118A (es)	2010-06-30
ZA201003430B (en)	2011-02-23
KR20100083170A (ko)	2010-07-21

Publication	Publication Date	Title
BRPI0809239A2 (pt)	2014-11-25	Análogos de pirazolopirimidina e seu uso como inibidores de quinase mtor e quinase p13
BRPI0813831A2 (pt)	2015-01-06	Compostos de heteroarila bicíclica e seu uso como inibidores de quinase
BRPI0912294A2 (pt)	2015-10-20	compostos de triazina como inibidores de pi3 quinase e de mtor
BRPI0920448A2 (pt)	2018-10-23	compostos spiro-oxindol e seu uso como agentes terapêuticos
BRPI1011066A2 (pt)	2017-03-21	"pirazolopirimidinas e heterociclos relacionados como inibidores de quinase
BRPI0815043A2 (pt)	2017-05-23	mcp-1 mutantes antagonistas de glicosaminoglicanos e métodos para o seu uso
BRPI0716749A2 (pt)	2014-02-18	Compostos pirido (2,3-d) pirimidinona e seu uso como inibidores pi3
BRPI0921156A2 (pt)	2016-02-23	inibidores de pi3k/mtor quinase
BRPI0906519A2 (pt)	2015-07-14	Compostos de 3h--[1,2,3]triazolo[4,5-d]pirimidina, seu uso como mtor cinase e inibidores de pi3 cinase, e sua síntese
BRPI1014572A2 (pt)	2016-04-26	imidazoprazinas para uso como inibidores de cinase
BRPI0716477A2 (pt)	2014-03-18	Derivados heteroarila como inibidores de quinase protéica
BRPI0719797A2 (pt)	2017-10-24	compostos e composições como inibidores de proteína cinase
BRPI0913580A2 (pt)	2015-10-20	pirrolopiridinas como inibidores de quinase
DK2004654T3 (da)	2013-07-22	Pyrazolopyrimidin derivater til anvendelse som kinase antagonister
BRPI0807893A2 (pt)	2014-06-17	Imidazoquinolinas como inibidores duais de lipídio quinase e mtor.
BRPI0911228A2 (pt)	2017-05-30	compostos e composições como inibidores de proteínas quinase
BRPI0815979A2 (pt)	2017-06-13	compostos e composições com inibidores de quinase, bem como uso dos mesmos
BRPI0820544A2 (pt)	2015-06-16	4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase
BR112013016030A2 (pt)	2018-07-24	compostos e seu uso como inibidores de bace
EP2111835A4 (en)	2012-10-31	VOIDABLE ARTICLE
BRPI0914652A2 (pt)	2017-06-06	compostos e composições como inibidores de quinase
BRPI0906444A2 (pt)	2015-07-14	Compostos de 4-piridinona e seu uso para câncer
BRPI0821027A2 (pt)	2015-06-16	4-(4-ciano-2-tioaril) dihidropirimidinonas e seu uso
BRPI0913885A2 (pt)	2015-08-25	Tiadiazoliloxifenilamidinas e seus uso como fungicidas
BRPI0916295A2 (pt)	2019-09-24	inibidores de pirazolopiridina tricíclica cinase

Legal Events

Date	Code	Title	Description
2015-06-09	B11A	Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
2015-09-08	B11Y	Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]